openPR Logo
Press release

Bleeding Disorders Treatment Market Expected to Grow at a CAGR of 8.4% by 2026 - Alnylam Pharmaceuticals, Amgen, Baxalta, Bayer, Biogen, Bristol-Myers

04-07-2020 06:01 PM CET | Health & Medicine

Press release from: Premium Market Insights

Bleeding Disorders Treatment Market is accounted for $11.14 billion in 2017 and expected to grow at a CAGR of 8.4% to reach $23.04 billion by 2026. Factors like growth in R&D investment for hemophilia products, inclination towards prophylactic treatment, increasing number of hemophilia patients, and the emergence of Biosimilars product are fuelling the market growth. Patent expiry of existing brands provide generic drug manufacturers an opportunity to enter, as well as sustaining healthcare infrastructure in developing economies with advancement in technology for development of new drugs and therapies will provide ample opportunity for the market growth. Market will also witness emerging trends like high entry barriers created by local government and low switching rate for hemophilia products. However, high cost of hemophilia drugs and inadequate reimbursement and lack of availability of skilled professionals are hampering the market growth.

By type, Hemophilia is a genetic disorder characterized by spontaneous hemorrhage or prolonged bleeding due to factor VIII or IX deficiency. Patients with more severe haemophilia suffer more severe and more frequent bleeds. Hemophilia is inherited in an X-linked recessive manner. The main therapy to treat hemophilia A is concentrated FVIII product, as clotting factor or simply factor. DDAVP (desmopressin acetate) is the synthetic version of vasopressin, a natural antidiuretic hormone that helps stop bleeding. Emerging trends in therapies are efficacy and safety assessments of established extended half-life (EHL) factor products and interest in Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies.

Get Sample PDF For More Professional And Technical Insights at:

https://www.premiummarketinsights.com/sample/SMRC00015910

North America is attributed to dominate the market during the forecast period owing to high acceptance for prophylaxis treatment among all age groups in the U.S. However, Asia Pacific is projected to grow at highest CAGR during the forecast period, due to increasing awareness of these disorders and availability of cheap generic drugs in the emerging economies such as India and China.

Some of the key players in Global Bleeding Disorders Treatment Market are Alnylam Pharmaceuticals, Amgen, Inc, Baxalta (Now Shire), Bayer Pharmaceuticals, Biogen Inc, Bristol-Myers Squibb Company, Cangene Corporation, CSL Behring, Grifols SA, Janssen Pharmaceuticals, Novo Nordisk A/S, Octapharma, Pfizer Inc., Sanofi and Xenetic Biosciences, Inc.
Drugs Covered:
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Plasma-derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Other Drugs

Types Covered:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Clotting Factor Deficiency

Therapies Covered:
- Medication Treatments
- Replacement Therapies

Regions Covered:
- North America
o US
o Canada
o Mexico
- Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
- Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
- South America
o Argentina
o Brazil
o Chile
o Rest of South America
- Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Purchase Complete Report at: https://www.premiummarketinsights.com/buy/SMRC00015910

Sameer Joshi
Call: +912067274191
Email: sales@premiummarketinsights.com

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bleeding Disorders Treatment Market Expected to Grow at a CAGR of 8.4% by 2026 - Alnylam Pharmaceuticals, Amgen, Baxalta, Bayer, Biogen, Bristol-Myers here

News-ID: 2002479 • Views:

More Releases from Premium Market Insights

Predictive Maintenance Market Analysis by Recent Developments and Business Outlook 2022-2028
Predictive Maintenance Market Analysis by Recent Developments and Business Outlo …
"The predictive maintenance market is projected to reach US$ 26,588.00 million by 2028 from US$ 5,316.99 million in 2021, growing at a CAGR of 27.4% from 2022 to 2028." According to The Premium Market Insights "Predictive Maintenance Market" report, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The Predictive Maintenance Market Research Reports offers an extensive collection of reports on
Endpoint Security Market Latest Trends, Technology Advancement and Demand 2022 to 2028
Endpoint Security Market Latest Trends, Technology Advancement and Demand 2022 t …
"The endpoint security market is expected to grow from US$ 14,951.39 million in 2022 to US$ 25,073.13 million by 2028; it is estimated to grow at a CAGR of 9.0% from 2022 to 2028." According to The Premium Market Insights "Endpoint Security Market" report, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The Endpoint Security Market Research Reports offers an
E-Learning Market Latest Trends, Advancement and Demands 2022 to 2028
E-Learning Market Latest Trends, Advancement and Demands 2022 to 2028
"The e-learning market is expected to grow from US$ 274.10 billion in 2022 to US$ 465.47 billion by 2028; it is expected to grow at a CAGR of 9.2% from 2022 to 2028." According to The Premium Market Insights "E-Learning Market" report, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The E-Learning Market Research Reports offers an extensive collection of
Investor ESG Software Market Growth and Latest Technology Advancements 2023 to 2030
Investor ESG Software Market Growth and Latest Technology Advancements 2023 to 2 …
"The investor ESG software market size is expected to reach US$ 2,340.13 million by 2030 from 627.85 million in 2022, with an estimated CAGR of 18.3% from 2023 to 2030." According to The Premium Market Insights "Investor ESG Software Market" report, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The Investor ESG Software Market Research Reports offers an extensive collection

All 5 Releases


More Releases for Hemophilia

Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia